Understanding how interferon works for treating myeloproliferative neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on classical BCR-ABL-negative myeloproliferative neoplasms (MPN) such as Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. It aims to investigate the mechanism of action of pegylated interferon alpha (Peg-IFNα2a) in patients diagnosed with MPN, particularly those with JAK2V617F and CALR mutations. The study will involve collecting blood samples from patients who are either newly diagnosed or currently undergoing treatment, to analyze their responses to the therapy. The goal is to better understand the variability in treatment responses and identify factors influencing efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult male or female 18 years of age or older
2. Diagnosis of MPN has been previously established by the referring physician and that physician will have decided to treat with pegylated IFN. Patients will be treated or untreated at the time of inclusion and may be newly diagnosed patients.
3. These patients will be affiliated with or benefit from a social security plan
4. For all these patients an additional 20-40 mL will be collected except for some PV patients who are treated conventionally by phlebotomy. In this case, we will collect blood bags from these patients. The volumes vary between 300 and 450 mL of blood depending on the weight and size of the patients.
5. We will also include in this protocol any patient whose MPN, either PV, TE or MF, will have progressed to acute leukemia (AL) during treatment. These will be patients with AP of MPN (MPN can also progress to acute myeloid leukemia (AML) by acute transformation (AT) of MPN).
6. Patient with signed informed consent

Exclusion Criteria:

1. The non-inclusion criterion concerns the anemia that some MF patients may suffer from. Therefore, patients with anemia (Hb\<10g) or transfusion dependency (≥ 1 packed red blood cell per month) at the time of the referral monitoring visit are not included in the research.
2. Persons under court protection, guardianship or curatorship

Where it's running

• Inserm U1287
  Villejuif, Île-de-France Region, France Recruiting

Study contacts

• Principal investigator: Florence Pasquier, MD,PhD — florence.pasquier@gustaveroussy.fr
• Study coordinator: isabelle Plo, PhD
• Email: isabelle.plo@gustaveroussy.fr
• Phone: +33 1 42 11 54 93

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Study of characteristics and complications in young patients with myeloproliferative neoplasia

  This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.

  Recruiting University Hospital, Brest · Brest · NCT06715267

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.